You are here

Boehringer Ingelheim Pharmaceuticals, Inc.

Member Since 2013

Jean-Michel Boers

President and Chief Executive Officer

Mr. Boers joined Boehringer Ingelheim in 1998 in Belgium, and advanced through various roles in corporate and operating units, including Corporate Vice President, Marketing and Sales Effectiveness, Country Managing Director for France and Human Pharma head of a European region consisting of mid-sized countries. Mr. Boers came to the U.S. in 2016 as Senior Vice President of the Specialty Care Franchise, and since January 2017, has led the U.S. Human Pharma business. He earned a master’s degree in social and economic history from the University of Nijmegen (Netherlands) and an MBA from the University of Texas.

CEO Cancer Gold Standard™

Gold Standard  Employer

Gold Standard Employer Since 2013 | Gold Standard China Employer Since 2015


We are truly honored to receive this Gold Standard certification to acknowledge our company-wide efforts to make wellness an integral part of our culture and fight cancer in the workplace. In addition to our efforts at home, we are committed to bringing more health to the oncology community, from our research and development of innovative cancer treatments to resources and initiatives that provide education and support to patients, caregivers and healthcare professionals.

— Jean-Michel Boers

Gold Standard  Task Force Participation

Task Force Subcommittee: Ann E. Burke, Executive Director, Benefits

Task Force Member(s): Tanya Kory, Vice President and Business Unit Head, Oncology

Global Gold Standard  Task Force Participation

Member Global Gold Standard Subcommittee: Ann Burke, Executive Director, Benefits

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Kevin Lokay, Vice President and Business Unit Head, Oncology

Further Support

Founding Member, CEO Roundtable on Cancer - China

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc. provides human prescription medicines. It offers pharmaceutical products for the treatment of lung health, cardiovascular diseases, men's prostate health, and anti-viral therapy. Its products include angiotensin II receptor blocker Micardis tablets for the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes; and COMBIVENT RESPIMAT, an inhaler for patients with chronic obstructive pulmonary disease. The company’s products also include Flibanserin for the treatment of hypoactive sexual desire disorder in pre-menopausal women; SPIRIVA HandiHaler for the reduction of exacerbations in patients with chronic obstructive pulmonary disease; pramipexole dihydrochloride extended-release tablet for the signs and symptoms of early idiopathic Parkinson's disease; Pradaxa for the observational study on management of deep vein thrombosis and pulmonary embolism; and Viramune XR (nevirapine) extended-release tablets for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. In addition, its products include Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes; volasertib, an investigational inhibitor of polo-like kinase for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia; insulin glargine products for diabetic patients; nintedanib, an investigational therapy for the treatment of people with idiopathic pulmonary fibrosis; and Glyxambi tablets to improve glycemic control in adults with type 2 diabetes. It has a strategic partnership with Humana Inc. and a strategic collaboration with Sarah Cannon Research Institute. The company was founded in 1971 and is based in Ridgefield, Connecticut with research and development facilities in Ohio, Virginia, Germany, and Italy. The company operates as a subsidiary of Boehringer Ingelheim Corporation.